Street Watch
Enzolytics Inc (OTCMKTS: ENZC) Running Up the Charts After Biotech Outlines Progress and Future Plans (Update on: Artificial Intelligence Diagnostics & ITV-1 and IPF Immune)
Published
2 years agoon
By
Boe Rimes
Enzolytics Inc (OTCMKTS: ENZC) is making an explosive move up the charts after the Company announced a progress update and more on its future plans. The Company spoke in depth of its work at Texas A&M University Institute for Preclinical Studies focused on the production of fully human monoclonal antibodies targeting multiple infectious diseases, including SARS-CoV-2 and HIV-1. Management also outlined the Company’s development of Artificial Intelligence for use in in-vitro diagnostic tests that diagnose viral diseases based on the presence of the conserved sites that remain unaffected by mutations. At Enzolytics’s Dallas laboratory, managed by Harry Zhabilov, the Company’s CSO who coordinates the development and the production of two of the Company’s primary therapeutics, ITV-1 and IPF Immune. Both therapeutics are produced under patents invented by Mr. Zhabilov, U.S. Patent Nos. 8,066,982, 7,479,538, and 8,309,072. ITV-1 is a therapeutic for treating individuals with HIV. It has been successfully produced and has been earlier successfully clinically tested in human trials under the Bulgarian Drug Agency requirements. The Company has also completed the production of IPF Immune, a product shown to function effectively as an immune booster.
ENZC is easily one of the most exciting stocks currently trading on the OTCQB. The stock was one of the biggest runners of 2021 skyrocketing to highs of of $0.958 and now that ENZC has reversed off $0.054 lows speculators are jumping back in and looking for something big here. ENZC has not disappointed so far running hard all day and closing at the high of the day (HOD), a very positive harbinger of things to come. Currently racing northbound, ENZC has huge liquidity, strong momentum and legions of investors from all over the world accumulating at current levels. Microcapdaily first reported on ENZC on September 16, 2020 just as it was taking off northbound after closing at $0.0009 the day before.
Enzolytics Inc (OTCMKTS: ENZC) is a drug development company committed to the commercialization of its proprietary proteins and monoclonal antibodies for the treatment of debilitating infectious diseases. The Company is advancing multiple therapeutics targeting numerous infectious diseases. Enzolytics has been building up a strong Advisory Board to support Enzolytics’ leadership team in achieving the Company’s goals and mission recently adding both Dr. Suraj Kumar Saggar and Dr. Lachezar Bogomilov Ivanov to its Advisory Board. Management is putting a lot of focus on its Intellectual Property portfolio which continues to grow. The focus is on gaining competitive advantage through an aggressive patent strategy. The Company owns patents protecting both ITV-1 and IPF Immune as well as patents in HIV, Coronavirus and a Artificial intelligence platform for use in diagnosing COVID-19.
One really exciting aspect of ENZC its its Artificial Intelligence platform which is being built under the leadership of Dr. Gaurav Chandra., the Company’s COO. The Healthcare A.I. market is expected to be 34 billion USD in 5 years. Enzolytics A.I. platform is unique because it has been driving the Company’s discoveries and Drug development. A.I. has helped Enzolytics move beyond big pharma’s monoclonal antibody discovery and development. As a result, Enzolytics continues to forge ahead with the immediate strategy to identify novel biomarkers and therapeutic targets, design innovative diagnostic and prognostics tests, and expand the Company’s Patent portfolio. Enzolytics’ long-term plan is to be a serious contender in the personalized medicine market.
ITV-1, Enzolytics’s therapeutic for treating individuals with HIV, is being successfully produced and has been earlier successfully clinically tested in human trials under the Bulgarian Drug Agency requirements. The Company has also completed the production of IPF Immune, a product shown to function effectively as an immune booster. Both ITV-1 and IPF are currently in production in accordance the precise methodology and specifications developed by Mr. Zhabilov. IPF Immune will now be available on the U.S. market. The Company IPF Immune dedicated website is expected to premiere this or next week. And the Company expects the product to be available in both large and small retail outlets as well as accessible from the dedicated IPF Immune website.
https://twitter.com/Demi6851/status/1519052657952010242
To Find out the inside Scoop on ENZC Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
With regard to the anti-HIV therapeutic ITV-1, the Company expects to be able to deploy the therapeutic initially in countries in Africa, followed by completion of EMA certification for use and distribution of the product for therapeutic use throughout Europe. The Company is also planning to launch IFP Immune in Europe and Canada. The Company has distributorship contacts in Europe and sees tremendous added potential from sales outside the U.S.
The Positive Therapeutic Effects of ITV-1 are numerous and include inhibiting the infection of CD4 T-cells by HIV, Reducing HIV viral loads, Replacing or complementing current anti-retroviral therapies. ITV-1 is potentially less costly and much less toxic and may be effective as a periodic therapy instead of a daily one. It is unaffected by HIV mutations that can hamper anti-retroviral therapies (HAART) and tests have shown a 80.5% drop in viral loads. It raises CD4 T-cell counts to healthier levels, a 68% increase in CD4+T-lymphocytes and has good compatibility with other anti-retroviral drugs. ITV-1 has benefits that antiretrovirals do not and may be used in situations where antiretrovirals are not appropriate.
The Company has engaged Scendea to assist in introducing ITV-1 to EU countries through the EMA and to North America through FDA. Scendea is a leading product development and regulatory consulting group serving the pharmaceutical and biotechnology industry. Scendea’s service will focus on reducing time-to-market and minimizing development costs. Scendea’s team offers strategic and operational support in quality/CMC, non-clinical/toxicology, clinical/medical, and regulatory, guiding the Company’s ITV-1 therapy efficiently to market approval.
The Company’s IPF Immune therapeutic is now entering the U.S. market. This science-backed immune modulator helps strengthen the body’s defenses against viruses or other pathogens. The product works as an immune booster that increases the ability of the immune system to fight infections by stimulating antiviral activity and helping to increase cell defense. The product supports the body’s immune system thereby enhancing recovery and reducing the recovery period after an illness. The Company is also planning to launch IFP Immune in Europe and Canada. The Company has distributorship contacts in Europe and sees tremendous added potential from foreign sales. This product enters the market as sales of American Dietary Supplements in North American reach $50.11 Billion. These sales are forecast to increase to $77.10 Billion in 2028. Enzolytics has engaged Nutritional Products International (NPI) to access this 50-billion-dollar market=Enzolytics IPF Immune will meet consumer needs due to its significant benefits.
#AI is the way & @enzolytics is the platform to watch.
It's exciting to read about company progress along with the industry leveling up as a whole with regards to policy change & new tech being accepted that would have previously just been seen as science fiction.$ENZC https://t.co/DgAjPbwz6r
— Jeff Taitano (@JeffTaitano) April 25, 2022
For more on ENZC Subscribe Right Now!
Currently trading at a $171 million market valuation ENZC has 2,830,435,953 shares outstanding of which 483,789,585 are restricted. For a biotech, the most explosive sector in small caps ENZC has good numbers with $2.23 million in the treasury and manageable debt including some convertibles. ENZC is easily one of the most exciting stocks currently trading on the OTCQB; moving up steadily since reversing off $0.054 lows, ENZC has a history of big moves skyrocketing to highs of $0.958 per share in February 2021 and it still boasts a massive following of investors accumulating at current levels who believe this one is going back up to where it was. While ENZC has gotten cheaper the underlying Company has been busier than ever. Currently ENZC subsidiary Virogentics, is seeing progress toward the production and use of its ITV-1, anti-HIV immunotherapy treatment in the Central and Eastern regions of Africa for patients with HIV/AIDS. Toxicology, pharmacodynamic and pharmacokinetic studies (toxicology studies) of the immunotherapy are planned, a prerequisite to use of the immunotherapy in certain African countries. These toxicology studies will also be used in the Company’s progress toward clinical trials necessary for EMA approval. The ITV-1 therapeutic has succeeded in clinical trials earlier and the Company is planning additional trials leading to EMA approval. ENZC could become a major player in the enormous $30 billion annual HIV market expected to reach $37 billion in the next 5 years. In a market primarily controlled by Gilead who sold $17 billion in HIV drugs last year Enzolytic’s HIV treatment is immunotherapy, not chemotherapy. One of the things that makes Enzolytic’s ITV-1 stand out from the pack is its safety profile. ITV-1 is really a form of immunotherapy that strengthens the immune system. Most of the HIV drugs are part of the Highly Active Antiretroviral Therapy (HAART) which does its best to use chemotherapy in multiple ways to disrupt the proliferation of the HIV virus. The point to make is all the drug has to do is keep the viral load at bay and the safety profile will be what drives the approval process forward. Don’t underestimate ENZC potential here, it’s a biotech right at 52 week lows, has one of the biggest audiences on the OTCQB, recent highs near $1 and is seeing significant progress with multiple upcoming catalysts in several different billion-dollar sectors. Microcapdaily first reported on ENZC on September 16 just as it was taking off after closing at $0.0009 the day before. We will be updating on ENZC when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ENZC.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in ENZC either long or short and we have not been compensated for this article.
You may like
-
Enzolytics Inc (OTCMKTS: ENZC) Biotech Reversal Underway As ITV-1 Gains Traction
-
Enzolytics Inc (OTCMKTS: ENZC) Coiled Tight Near 52 Week Lows as Biotech Looks to Disrupt Several Enormous Markets (ITV-1 for HIV, Monoclonal Antibodies & AI)
-
Enzolytics Inc (OTCMKTS: ENZC) Powerful Reversal Underway as Immune™ Goes International in Booming Nutritional Supplement Market
-
Enzolytics Inc (OTCMKTS: ENZC) Major Reversal Brewing as Biotech Gains Traction in HIV Market (Update on: ITV-1 EMA Approval, ITV-1, anti-HIV Treatment & IPF Immune US Launch)
-
Enzolytics, Inc. (ENZC) Big Reversal Northbound as Biotech Launches IPF Immune & Plans Immune Therapeutic ITV-1 for Clinical Trials
-
Top Covid Stocks In Play After Pfizer Vaccine Approval: TOMDF ENZC TSOI
Featured
The Crypto Company (OTC: CRCW) Skyrockets 1000%: Understanding the Surge and Potential Impact
Published
3 days agoon
December 5, 2023
The Crypto Company (OTC: CRCW) has experienced a significant upswing, with a staggering increase of over 1000% within just a few weeks. Despite this dramatic movement, there seems to be no noticeable impact from any major press releases driving these fluctuations. However, numerous filings on the OTC Markets are available for review, potentially holding significance in explaining this sudden surge.
X, a commonly used platform by OTC companies for investor updates, has also not seen active utilization in this scenario. Nevertheless, there has been a noticeable uptick in engagement from investors on the platform.
As CRCW crosses the one-cent-per-share mark, there arises a pertinent question: Can this momentum be sustained, potentially pushing the stock to even higher levels? Examining various factors, including forthcoming prospects and market dynamics could shed light on their trajectory – as always, we’ll start with some background first.
Background:
Given CRCW’s website is currently under construction, we’re basing our background analysis on one of their filings. Before we dig deeper, it’s important to note that CRCW is registered with the SEC and adheres to their rigorous reporting standards. This is a positive aspect for investors, enhancing transparency across the board.
As mentioned, we found their background from an excerpt on their 10-Q filing. Which states that the Crypto Company was established in Nevada on March 9, 2017 and their focus in the business of Bitcoin mining, consulting, training, education, and associated services concerning distributed ledger technologies, commonly known as “blockchain.”
They have a wholly-owned subsidiary, Blockchain Training Alliance where all their courses and training packages can be found. It appears this is the entity in which most of their business is conducted.
These services cater to both corporate and individual clients, emphasizing general blockchain education and the development of technological infrastructure and solutions for enterprise-level blockchain technology. The company’s primary sources of revenue and expenses stem from consulting and educational related operations.
Market Dynamic:
The crypto market’s performance this year has been remarkable. For those not closely following, it has surged by over 150% in just a single year… With Bitcoin’s lows in January, much of the online chatter was pessimistic, painting the digital asset as a futile investment destined to vanish into nothingness and hold no value. Of course all that has changed and a number of market dynamics have pushed positive momentum to the digital asset.
Just recently, there’s quite a significant rumour going around, that Qatar’s Sovereign Wealth Fund is evaluating a $500 Billion Bitcoin Investment. This has in turn fuelled a market frenzy and pushed BTC over 10% in 4 days.
As per a user, @seth_fin, on X, an investment of this scale could potentially propel the value of BTC to over $150,000 per coin. This represents a substantial increase of approximately 255% from the current value of $42,298 at the time of writing.
Other macro possibilities are at stake as well, with the possibility of a spot BTC Blackrock ETF, and BTC halving in April 2024. These advancements have generated substantial excitement within retail investor communities, to say the least.
The importance of this market dynamic is simple. In a booming market, all entities tend to benefit. Considering CRCW as a micro cap OTC company in the cryptocurrency realm, there’s a possibility it could also gather momentum. Given its low share value, the observed volatility can be quite intense, as evident from the recent fluctuations over the last couple of weeks.
Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
OTCM Filings:
As previously mentioned, the company has put out numerous filings in recent weeks. Here are a couple that warrant your attention.
Insider Purchase:
CRCW put out an 8-K on November 24th, 2023. Here’s the exact statement from the filing, “Effective November 24, 2023, the Crypto Company (the “Company”) agreed to convert $49,600 of accrued but unpaid salary for Ron Levy, the Company’s Chief Executive Officer, Interim Chief Financial Officer, Chief Operating Officer and Secretary (“Mr. Levy”), to Common Stock of the Company at a conversion rate of $0.0016 per share (the “Conversion Price”), resulting in an aggregate of 31,000,000 shares of Common Stock of the Company (the “Conversion Shares”) being issued to Mr. Levy. The Conversion Price was based upon a five-day volume-weighted average price of the Company’s Common Stock and approved by the Company’s independent board member.”
Insider purchases are good for a number of reasons, specifically:
- Confidence and Alignment: Insider purchases often signal confidence in the company’s future prospects. When executives, directors, or employees buy shares of their own company, it demonstrates that they believe in its potential for growth and success. This action aligns the interests of insiders with those of shareholders, indicating a shared belief in the company’s performance.
- Positive Signal: It can serve as a positive signal to the market. Public disclosure of insider purchases can create a favorable impression among investors, indicating that those closely involved with the company view its stock as undervalued or anticipate positive developments.
- Information Signal: Insider purchases might suggest that those with the most intimate knowledge of the company’s operations and potential future plans see favorable outcomes ahead. This information can be perceived by outside investors as a cue to the company’s expected performance.
10-Q filing:
It’s crucial to evaluate financial stability unveiled in 10-Q filings. As for CRCW, there appears to be underlying risk factors involved with their financial health. This is a frequent occurrence among OTC companies trading in the Pink tier and a common risk taken for companies in a high growth phase. With other positive indicators, it doesn’t automatically imply you should stay away, but these are figures you should be aware of:
- Total Revenue 3 months ended September 30th 2023 USD $124,195 compared to USD $252,733 the year prior
- Net loss 3 months ended September 30th 2023, (USD $358,845 ) compared to (USD $415,737 ) the year prior
- Total current assets September 30th, 2023 $1,306,324 compared to $1,556,561 December 31st, 2022
- Total Liabilities September 30th, 2023 $5,211,421 compared to $4,616,001 December 31st, 2022
As of September 30, 2023, the Company had cash of USD $20,435. In addition, the Company’s net loss was (USD $3,922,996) for the nine months ended September 30, 2023 and the Company’s had a working capital deficit of USD $5,048,726.
Technical Analysis:
The surge in trading volume of CRCW has attracted a considerable influx of technical traders seeking potential entry points. The recent volume reached an impressive 74,807,398 shares traded, marking over a 5.5x surge compared to its average 3-month volume of 13,674,352.
While technical analysis is commonly favoured by day traders seeking quick flips or swing trades, it plays a pivotal role in enhancing market liquidity for all investors.
According to insights from users like @jennyjunechris, there seems to be a shift in support and resistance levels. Their perspective indicates that CRCW may have established a new support level after successfully surpassing prior resistance thresholds.
Resistance levels, integral in technical analysis, represent price levels where a stock encounters selling pressure, hindering its upward momentum. These levels signify areas where the price struggles to ascend, potentially indicating a barrier preventing further upward movement.
Traders and analysts identify these levels through historical price patterns, chart analysis, and market behaviour. Approaching a resistance level often triggers heightened selling activity, as previous buyers may sell to lock in profits, potentially stalling or reversing the asset’s ascent.
Understanding resistance levels is pivotal for traders, indicating potential selling opportunities. Failure to breach a resistance level might suggest a stall or reversal in an asset’s upward trajectory. Conversely, a convincing breakthrough above a resistance level could signal a continuation of a bullish trend.
Trading Algorithms:
As mentioned, CRCW experienced a notable surge without any significant press releases or SEC filings today. Much of this momentum seems to stem from increased demand among retail investors and a surge in hype, which could potentially impact trading algorithms.
This sudden surge in the market, characterized by rapid price fluctuations, has the potential to prompt algorithms to react aggressively, thereby amplifying market volatility. Additionally, the high trading volumes observed within a short timeframe could trigger algorithms designed to respond to volume changes, further magnifying price swings.
Moreover, trading algorithms commonly rely on technical analysis, reacting swiftly to signals from various charts, indicators, and trading patterns. Abrupt changes in these technical indicators might trigger rapid algorithmic responses, contributing to the overall market turbulence.
Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Material Press Release:
Since June 26, 2023, the company hasn’t issued any press releases, but one stands out as a significant event from 2022. CRCW secured a substantial deal with a company associated with Fortune 500 companies.
Given the prevailing macroeconomic factors, there’s a growing demand for a deeper comprehension of cryptocurrency as a whole, this is precisely where CRCW’s educational packages become highly relevant and it’s possible their wholly owned subsidiary will be well positioned to take advantage of increased demand.
Oct. 26, 2021 Release:
CRCW announced that its wholly owned subsidiary, Blockchain Training Alliance, has partnered with Hired to supply candidates for referral in the high-demand blockchain space. Hired is a service provider to industry leaders such as Instacart, Wayfair, Zendesk, Postmates, Twitch, Capital One, and Peloton.
Demand for blockchain skills is a rapidly growing IT skill set, and the Blockchain Training Alliance is a global leader in instructor-led blockchain training and certifications. It provides relevant content, instruction, and certifications for blockchain technology as the use of blockchain continues to grow in the corporate world.
“We are thrilled to enter into this new agreement with Hired as it solidifies our position with a major employment company,” said Ron Levy, CEO of The Crypto Company. “Blockchain Training Alliance is arguably the #1 blockchain training company in the world, and I believe we are experiencing the largest migration of talent in history into one industry and that industry is blockchain. My team is at the forefront of training that talent pool, so, it makes perfect sense that we help source candidates to one of the leaders of the talent marketplace.”
Since this announcement, there’s been a noticeable crypto market downturn, commonly referred to as the “crypto winter.” However, with renewed enthusiasm for the crypto space, there’s potential for this deal to attract increased deal flow. While an update from the company regarding this would be appreciated, the deal remains intriguing and could potentially drive substantial long-term growth.
Conclusion:
In summary, the prevailing positive market dynamics hint at a potential upswing for crypto companies in general, including micro cap OTC entities like CRCW, poised to reap the benefits. Naturally companies like CRCW will have extreme volatility, potentially leading to monumental 1000% gains, or entire loss of your investment. Some positive filings reveal significant insider activity and have drawn attention from a robust retail community. Coupled with the Hired announcement, we find CRCW particularly intriguing with long-term growth prospects. As is customary in this swiftly evolving space, we advise closely monitoring CRCW for any rapid developments.
We will update you on CRCW when more details emerge, subscribe to Microcapdaily to follow along!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Picture by TheDigitalArtist from Pixabay
Featured
Uncovering CS Diagnostics (OTC: FZRO): Behind the 117% Gain & Market Opportunity
Published
1 week agoon
November 28, 2023
CS Diagnostics Corp. (OTC: FZRO) has seen a remarkable 112% surge in its shares as of the current moment, marking a staggering total gain of 432% since November 15th, 2023. Interestingly, despite this significant increase, the company hasn’t released any press statements and we cannot find any respective SEC filings that could account for such a surge.
The absence of an investor relations section on the company’s website limits the available avenues for gathering insights. Nonetheless, we managed to uncover additional information through online forums among retail investors and a supplemental filing from the OTC markets website, posted from FZRO’s Twitter.
While these sources have provided some background, the lack of formalized information leaves us with relatively little to base our analysis on. Nonetheless, despite its recent nature, the supplementary OTC filing dated November 27th, 2023, could potentially offer a preview of FZRO’s future prospects and the potential trajectories it might pursue.
Background:
On September 4, 2023, CS Diagnostics Corp made a significant acquisition. They purchased the entire CS Protect-Hydrogel, including its tangible product, intellectual property, distribution rights, and patents from the CS Diagnostics Group, a company based in Germany. This hydrogel-based tissue spacer serves a crucial purpose in radiation therapy by creating distance between cancerous cells and healthy tissue. Essentially, it shields healthy tissue from the harmful effects of high doses of radiation.
Hydrogel Spacers:
Currently hydrogel spacers are specifically used in treating prostate cancer. In this case, the spacer helps in moving the rectum away from the prostate, thereby decreasing the damage caused to the rectum during radiation therapy. This hydrogel spacer is injected in liquid form through a thin needle into the area between the cancer cells and healthy tissue. It gradually dissolves within the body after approximately 6 months.
What’s unique about CS Protect-Hydrogel is that it’s a ready-to-use product, sterilely packed and can be directly applied. Moreover, this hydrogel can be beneficially utilized in radiotherapy treatments for a wide array of cancers such as prostate, cervical, esophageal, bladder, and breast cancers.
Competitive landscape:
Good news, there does not appear to be a highly competitive landscape for this technology. FZRO’s main competitor for hydrogel spacers would be Boston Scientific Corporation (NYSE: BSX), currently valued at USD $80 billion. The competitor product SpaceOAR Hydrogel System was developed in 2010 by Augmentix, Inc., which was fully acquired by Boston Scientific Corporation in 2018 for a fixed purchase price of USD $500 million plus a variable purchase price component of USD $100 million upon achievement of certain sales targets.
The competitor product has been further developed, and is currently marketed under the SpaceOAR Vue Hydrogel trademark, and is approved exclusively for use in prostate radiation. The product marketed by BSX consists of three components that are mixed in a predetermined sequence and drawn into a syringe by a trained and skilled person.
It’s important to note that the molecule of the CS Protect-Hydrogel differs significantly from the molecule of the competitor product, and patent infringements are not to be expected.
Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Competitive Edge:
According to FZRO, their product is highly differentiated from BSX and comes with several advantages, specifically:
Practical Benefits:
- Effortless application of CS Protect-Hydrogel as it comes pre-prepared, simplifying the process.
- Eliminates any additional work steps.
Hygienic Advantages:
- Immediate application of CS Protect-Hydrogel upon removal from sterile packaging, minimizing the risk of contamination.
- Prevention of contamination from product preparation and assembly.
- Reduction of potential hygienic risk areas within the treatment room.
Medical Benefits:
- Elimination of the risk of incorrect mixture, preventing potential missed patient appointments.
- Expanded application across various cancers (prostate, cervical, esophageal, bladder, and breast), enabling a broader range of treatments.
- Feasibility of hypofractionation, reducing the number of treatment sessions per patient.
- Potential for dose escalation, facilitating acceleration of radiation therapy.
Economic Benefits:
- Reduced personnel costs during treatment by removing the need for assistance in hydrogel mixing.
- Lower room utilization costs per patient due to decreased risks of re-treatment from incorrect mixtures.
- Decreased cleaning expenses due to the ready-to-use nature of the product.
- Minimized lawsuits or insurance claims resulting from incorrectly mixed hydrogels, reducing additional treatment requirements.
- Lower purchase price for clinics compared to competitor products.
With easier handling, lower medical & cost risks, and expanded scope of application, FZRO expects that the respective purchasing departments of clinics (including specialty clinics) and hospitals will quickly adopt and list the CS Protect-Hydrogel in their portfolios.
Market Opportunity:
Apart from the CS Protect-Hydrogel, a competitor product enjoys widespread global use. The CS Diagnostics Group is confident that the CS Protect-Hydrogel could capture around 50% of the market share in the near future. This confidence stems from the aforementioned easier handling, reduced medical and cost risks, and broader range of applications.
The success of the CS Diagnostics Group’s use of CS Protect-Hydrogel relies heavily on how well it enters the market and the share it captures.
In a realistic scenario where it achieves a 50% market share and respective sales prices of EUR $1,100 and USD $1,900 per unit, the economic benefit as the net present value of future cash surpluses as of September 30, 2023 is a monumental EUR $961 million.
For more information on how this was calculated, click here.
Valuation & Audit:
On September 4, 2023, Tom Wrankmore, a reputable German public auditor and valuation firm, conducted an assessment certifying the value of the CS Diagnostics Hydrogel product, all previously mentioned values were taken from Wrankmore’s assessment.
It’s important to remember there’s a number of x factors involved in the valuation of FZRO, and the values calculated could be no where close to accurate if things do not go according to plan.
Considering Wrankmore’s credible expertise and esteemed status, he perceives this scenario as a plausible one. However, the successful execution ultimately falls on the management team.
It’s crucial to delve into the team’s background and track record to gauge the potential outcome accurately. Presently, there’s limited information available about the management team, which isn’t necessarily a surprise, given how recent FZRO was established.
Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Acquisition & Approvals:
On September 27, 2023, CS Diagnostics Corp acquired the entire CS Protect-Hydrogel for a cost basis of Five Hundred Million USD. This acquisition was completed through the issuance of 110,000,000 shares of CS Diagnostics Corp Common Stock. Following this transaction, in November 2023, CS Diagnostics Corp submitted its 3rd Quarter Report and Financial Statements, emphasizing the acquisition of the CS Protect-Hydrogel.
This submission aimed to clarify that the company is no longer categorized as a shell company and should not be considered a “Shell Risk.”
At present, the company is actively collaborating with its partners to secure regulatory approval for CS Protect-Hydrogel from key authorities across Europe, North, and South America. This critical step is essential for the product’s recognition and acceptance in medical applications within these regions.
Following successful CE testing and certification in Germany, the process of registration or approval involves a necessary testing procedure. Anticipating the regulatory journey, the CS Diagnostics Group expects a timeframe of 6 to 12 months for approval in the U.S. Additionally, a timeline of 6 to 8 months is foreseen for the testing procedure and registration of CS Protect-Hydrogel in Germany.
Considering the existing market availability of a competitor product used worldwide specifically for prostate irradiation, CS Protect-Hydrogel does not require extensive re-introduction or advertisement for this particular application. However, extensive information dissemination and promotional efforts are crucial for establishing its use in treating other types of cancer.
Conclusion:
Obviously FZRO is still in its early phases, but Wrankmore’s assessment has certainly made it quite attractive. While it’s currently too soon to tell, we can imagine part of FZRO’s exit strategy may consider a bigger player like Boston Scientific Group (NYSE: NSX) buying them out – this all depends on how FZRO progresses and is merely speculation for now.
The recent OTC filing on November 27th, 2023, has caught the eye of many retail investors, sparking interest in the stock. Volume is picking up extremely quickly and we might not see these low levels for long. FZRO’s average trading volume is 4,514 shares and had 179,680 shares traded at the time of writing – a near 40X increase in volume after Wrankmore’s assessment.
Over the next 6 to 8 months, we expect to gain clearer insights into how well the management team can meet Wrankmore’s expectations. Regardless, we strongly advise closely monitoring FZRO during this pivotal period, as developments tend to evolve rapidly.
We will update you on FZRO when more details emerge, subscribe to Microcapdaily to follow along!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Featured
Boardroom Battles and AI Fears: The OpenAI Story Unfolded
Published
2 weeks agoon
November 21, 2023
Introduction:
Picture a blockbuster-style movie or binge-worthy TV series where there’s a secretive board takeover, worries about AI gone rogue, a CEO feeling the sting of betrayal from his own crew, and a late-night rebellion rocking the global tech stage. Sounds like an unbelievable storyline…. doesn’t it? But this isn’t some made-up tale—it’s the real deal and a very recent development at OpenAI.
For those not knee-deep in the whirlwind of developments, catching up on this roller-coaster ride can be quite a task. But this story matters, even if you’re not an A.I. enthusiast. Whether you’ve interacted with ChatGPT or pondered the risks of powerful A.I., all these threads are woven into the OpenAI drama—a company leading the charge in artificial intelligence innovation.
What sparked the chaos?
Last Friday, OpenAI’s CEO, Sam Altman, got the boot. The reason? Vague murmurs about his lack of transparency with the board. Interestingly enough, OpenAI has a nonprofit board that controls the for-profit subsidiary and can vote to replace leaders if necessary. This structure is what allowed the removal of Altman without explaining much.
Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Why the upheaval?
The upheaval began with Ilya Sutskever, OpenAI’s chief scientist, locking horns with Altman. Sutskever wanted safety prioritized; he feared Altman was chasing growth without caution. This difference of opinion mirrored a broader split among A.I. experts—some worried about A.I. outpacing humans, while Altman was more optimistic about its potential.
What came next?
Speculations about Altman’s return faded fast. Interim CEOs shuffled in and out, with Microsoft dangling job offers for Altman and his colleague, Greg Brockman who was also removed as chair of the board and decided to quit in solidarity alongside Altman hours later. The move prompted almost everyone at OpenAI to threaten quitting unless Altman and Brockman were reinstated.
Twitch’s co-founder Emmett Shear became the newly appointed interim CEO and mentioned that prior to taking up the role, he asked about the reasons behind Altman’s removal. Shear clarified that the board’s decision to oust Sam didn’t stem from any particular safety-related dispute. “Their rationale was entirely distinct from that,” Shear stated. Unfortunately he refrained from providing any specifics regarding what that reasoning might have entailed.
In a weekend memo addressed to the staff, even Brad Lightcap, OpenAI’s chief operating officer, clarified that the board’s choice “wasn’t a response to wrongdoing or anything linked to our financial, operational, safety, or security/privacy approaches. It was a breakdown in communication between Sam and the board.”
In a plot twist, Sutskever expressed regret, trying to mend fences after his name popped up among almost 500 staff members on a letter threatening to quit unless Altman was brought back. Within’ a few hours, ~95% of the company had jumped on board with this sentiment.
His post on X states, “I deeply regret my participation in the board’s actions. I never intended to harm OpenAI. I love everything we’ve built together and I will do everything I can to reunite the company”.
Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Why does this matter to us?
This isn’t just another corporate spat. OpenAI isn’t your run-of-the-mill company—it birthed ChatGPT and houses top-notch A.I. researchers. Their aim? Crafting super-smart A.I. Altman’s clout in the A.I. world added a layer of intrigue to his sudden exit.
Zooming out, this turmoil mirrors a bigger struggle: how to regulate powerful A.I. tools and trust companies to use them responsibly.
But the big question remains: Why was Altman removed?
The board’s explanation about communication gaps didn’t clarify much. The twists and turns offered no clear answers. Rumors about reckless A.I. development were debunked. Sutskever’s remorse seemed to contradict safety concerns.
As things settle, Microsoft’s CEO remains in the dark but still trusts Altman’s leadership, adding more mystery to the puzzle.
Altman, a founding force, transformed OpenAI from a research hub to an A.I. powerhouse. The recent turmoil paints a stark contrast to their journey, raising concerns within the board that led to Altman’s abrupt exit.
The OpenAI saga is a real head-scratcher—a once-quirky lab now entangled in a real-life puzzling tale, leaving everyone wondering what triggered this unprecedented shake-up.
We will update you as more details emerge, subscribe to Microcapdaily to follow along!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Picture by geralt from Pixabay
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Recent Posts
Bitfarms (NASDAQ: BITF) in Focus: Exploring the Meteoric 110% Surge and Macro Influences
The Crypto Company (OTC: CRCW) Skyrockets 1000%: Understanding the Surge and Potential Impact
BlockQuarry Corp’s (OTC: BLQC) Exponential Growth: Understanding the Phenomenon
Brainstorm Cell Therapeutics’ (NASDAQ: BCLI) Post-Setback Resurgence: Unpacking FDA Impact & Market Expectations
iSun, Inc (NASDAQ: ISUN) on the Rise: Recent Market Growth & Remarkable Momentum
Trending
-
Uncategorized1 year ago
Meta Materials Inc (OTCMKTS: MMTLP) Enormous Short Position in Trouble as Next Bridge Hydrocarbons Set to Stop Trading (George Palikaras & John Brda on Corporate Action)
-
Micro Cap Insider2 years ago
Medium (KOK PLAY) The Parabolic Rise of Metal Arts (OTCMKTS: MTRT)
-
Media & Technology3 years ago
Healthier Choices Management Corp. (OTCMKTS: HCMC) Powerful Comeback Brewing as PMI Patent Infringement Lawsuit Moves Forward
-
Media & Technology3 years ago
AMECA Mining RM; the Rise of Southcorp Capital, Inc. (OTCMKTS: STHC)
-
Media & Technology2 years ago
SNPW (Sun Pacific Holding Corp) Power Brewing: 50MW solar farm project in Durango Mexico MOU with Atlas Medrecycler 48,000 SF New Partnership Queensland Australia Solar Farm.
-
BioPharma2 years ago
Asia Broadband (OTCMKTS: AABB) On the Move Northbound Since Sub $0.08 Dip as Crypto Innovator Elevates AABB Crypto Exchange & Enters the NFT Space
-
Uncategorized1 year ago
Meta Materials Inc (OTCMKTS: MMTLP) Short Squeeze S-1a4 Filing Signals S1 Approval Could Be Days Away (Next Bridge Hydrocarbons Spin-Off)
-
BioPharma2 years ago
Humbl Inc (OTCMKTS: HMBL) Major Reversal as Powerful Advisor Rejoins the Team & Looks to Uplist to Major Exchange